30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

1Q13 Revenue: Seikagaku

(For fiscal year 2012 ended 3/13/13)

¥26.6BB (~US $262.7MM), -2% (Domestic ~$175.2MM, -1%; Overseas ~$38.8MM, +12%)

FY4Q12 revenue: ¥5,984MM (~US $61.4MM), -1%

  • Japan and China markets expanded for ARTZ knee osteoarthritis injectable, while U.S. sales of SUPARTZ product fell due to reimbursement restrictions on multiple-injection formula products
  • Completed case registration for Phase III Japan clinical trial of SI-6603 treatment for lumbar disc herniation; study now in observation period; initiated Phase III clinical trial of SI-6603 in U.S.
  • Commenced case registration in Japan for SI-613 treatment for knee osteoarthritis: hyaluronic acid + NSAID